Scisparc Ltd - ESG Rating & Company Profile powered by AI
If you are employed by Scisparc Ltd and you would like to use your Sustainability aseessment, please contact us. Other corporations in the scoring peer group for Scisparc Ltd are shownin the table. Comprehensive ESG assessment of Scisparc Ltd are accessed by signing in.
Scisparc Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.9; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.7.
0.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1810 | XBiotech Inc | 1.1 | Low |
| 1826 | Mitsubishi Tanabe Pharma Corp | 1.0 | Low |
| 1827 | Scisparc Ltd | 0.9 | Low |
| 1827 | CannTrust Holdings Inc | 0.9 | Low |
| 1827 | Cannabis Poland SA | 0.9 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Scisparc Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Scisparc Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Scisparc Ltd report the average age of the workforce?
Sign up for free to unlockDoes Scisparc Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Scisparc Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Scisparc Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Scisparc Ltd offer flexible work?
Sign up for free to unlockDoes Scisparc Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Scisparc Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Scisparc Ltd conduct supply chain audits?
Sign up for free to unlockDoes Scisparc Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Scisparc Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Scisparc Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Scisparc Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Scisparc Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Scisparc Ltd disclose water use targets?
Sign up for free to unlockDoes Scisparc Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Scisparc Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Scisparc Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Scisparc Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Scisparc Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Scisparc Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Scisparc Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Scisparc Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Scisparc Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Scisparc Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Scisparc Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Scisparc Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Scisparc Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Scisparc Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Scisparc Ltd disclose its waste policy?
Sign up for free to unlockDoes Scisparc Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Scisparc Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Scisparc Ltd disclose energy use targets?
Sign up for free to unlockDoes Scisparc Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Scisparc Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Scisparc Ltd
These potential risks are based on the size, segment and geographies of the company.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.